Presentations on seroadaptation
- HIV Seroadaptation Is a Frequent Sexual Harm Reduction Strategy for MSM. Hong-Ha Truong, Y-H Chen, F Raymond, B Nguyen, J Mehrtens, G Colfax, T Robertson, R Stall, D Levine, and W McFarland
- Seroadaptive Tactics Adopted by HIV+ MSM Can Contribute to Profound and Sustained Reductions in HIV Transmission Risk following HIV Diagnosis. Snigdha Vallabhaneni, L Loeb, L Bragg, J McConnell, W Hartogensis, R Grant, F Hecht, and C Pilcher
- Success of Test and Treat in San Francisco? Reduced Time to Virologic Suppression, Decreased Community Viral Load, and Fewer New HIV Infections, 2004 to 2009. Moupali Das, P Chu, G-M Santos, S Scheer, W McFarland, E Vittinghoff, and G Colfax
- Directly Observed Weekly Fluoxetine Improves Unannounced Pill Count Antiretroviral Adherence and Mood in HIV+ Depressed, Homeless/Marginally Housed Individuals. David Bangsberg, A Tsai, D Karasic, G Hammer, E Charlebois, K Ragland, A Moss, J Sorensen, and J Dilley
- HIV-infected Ugandan Children Randomized to Switch from NNRTI- to LPV/r-based ART Maintain Virologic Suppression and Stable CD4 levels. Jane Achan, T Ruel, G Ikilezi, A Kakuru, G Dorsey, P Rosenthal, E Charlebois, D Havlir, and M Kamya
- Kinetically Guided pegIFN and RBV Therapy for HIV+ Adults Co-infected with Acute HCV. B Hare, Kristen Marks, A Luetkemeyer, E Charlebois, G Cloherty, M Glesby, A Talal, D Havlir, and M Peters
- Drug Resistance and Minor Drug Resistant Variants in iPrEx. Teri Liegler, M Abdel-Mohsen, R Atchison, M Mehotra, T Schmidt, C Eden, D Glidden, S Buchbinder, J Lama, R Grant, and iPrEx Study Team
Last modified: November 2, 2012